恩替卡韦序贯聚乙二醇化干扰素-α与单用恩替卡韦治疗慢性乙型肝炎的临床疗效比较:系统评价与分析

Comparison of clinical efficacy of entecavir-sequential Peg-IFN-αand entecavir alone for treatment for chronic hepatitis B:systematic evaluation and analysis

目的系统评价与分析恩替卡韦(ETV)序贯聚乙二醇化干扰素-α(Peg-IFN-α)与单用ETV在治疗慢性乙型肝炎患者中的临床疗效。方法计算机检索PubMed、Embase、Cochrane Library、中国知网、万方数据库,搜索有关ETV及ETV序贯Peg-IFN-α治疗慢性乙型肝炎的随机对照试验研究,应用Stata 16.0软件对符合纳入条件的临床研究进行系统评价与分析。结果共纳入10篇文献,1250例患者,其中553例患者采用ETV序贯Peg-IFN-α治疗,697例患者单用ETV治疗,两组患者组间基线特征比较,差异均无统计学意义(均P>0.05)。ETV序贯Peg-IFN-α试验组的HBsAg转换率、HBsAg清除率、HBeAg转换率、HBeAg清除率均高于ETV对照组,差异均有统计学意义(均P<0.05)。结论在慢性乙型肝炎抗病毒治疗中,总体上ETV序贯Peg-IFN-α治疗疗效优于单用ETV。

Objective To systematically evaluate and analyze clinical efficacy of entecavir-sequential pegylated interferon-α(ETV-sequential Peg-IFN-α)and ETV alone for treatment of patients with chronic hepatitis B(CHB).Methods Randomized controlled trial on ETV and ETV-sequential Peg-IFN-αfor treatment of CHB were searched from PubMed,Embase,Cochrane Library,China National Knowledge Infrastructure Construction(CNKI)and Wanfang database by computer,clinical studies that met the inclusion criterion were systematically evaluated and analyzed by Stata 16.0 software.Results A total of 10 literatures were included,involving 1250 patients,553 of whom were treated with ETV-sequential Peg-IFN-α,697 patients were treated with ETV alone,there was no significant difference in baseline characteristics between two groups of patients(all P>0.05).HBsAg conversion rate,HBsAg clearance rate,HBeAg conversion rate and HBeAg clearance rate in ETV-sequential Peg-IFN-αtrial group were all higher than those in ETV control group,differences were statistically significant(all P<0.05).Conclusion In the antiviral treatment of CHB,therapeutic effect of ETV-sequential Peg-IFN-αis better than that of ETV alone.